Objective: To probe into the pharmaceutical care method of adrenocorticotropic hormone (ACTH) in the treatment of epileptic spasm and the countermeasures of adverse events. Methods: Before ACTH treatment

the neutrophil/lymphocyte ratio of two children were less than 0.5

and the prealbumin (0.25 g/L) increased abnormally

which indicated these children might associate with high risk of hypertension during ACTH treatment. The clinical pharmacist formulated pharmaceutical care regimen in advance

the clinicians and clinical pharmacists jointly carried out 24 h pharmaceutical care to ensure the safety of treatment. Results: Hypertension were developed in both children during ACTH treatment and were improved with the administration of captopril. In addition

one case presented with thrombocytosis (reactive and improved) and one case with cough (improved after symptomatic treatment with nebulization). Conclusion: Attention should be paid to blood pressure and immune-related pharmaceutical care during the treatment of epileptic spasm with ACTH.